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Abstract The fate of newly synthesized human immunodefi- 
ciency virus type 1 env  gpl60 was examined in COS-1 cells. The 
results of morphological chase experiments involving cyclohex- 
imide demonstrated that gpl60 was retained in the Golgi 
apparatus for longer than the half-life of the molecule. The 
degradation of gpl60 was insensitive to both bafilomycin A1 and 
leupeptin (<0.2 mM), which block lysosomal proteolysis. 
However, degradation was effectively suppressed by leupeptin 
at higher concentrations, maximally at 1.7 mM. Furthermore, 
undegraded gpl60 was accumulated in the Golgi apparatus, but 
was not detected in lysosomes. These results indicate that in 
COS-1 cells gpl60 is not degraded in lysosomes, but rather that 
degradation takes place in the Golgi apparatus. 
Key words: HIV-1; env gpl60; Degradation; 
Golgi apparatus 
1. Introduction 
During the transport of human immunodeficiency virus 
type 1 (HIV-1) envelope glycoproteins through the secretory 
pathway, the precursor polyprotein, env gpl60, is cleaved into 
noncovalently associated external gpl20 and membrane-span- 
ning gp41 subunits. The cleavage is an essential step in the 
maturation of the glycoprotein into a functional complex 
[1,2], and takes place in the Golgi apparatus [3,4]. Although 
the cleavage fficiency depends on the host cells or strain of 
virus used [5], the processing of gpl60 into the gpl20-gp41 
complex normally occurs in a very inefficient manner in both 
peripheral blood lymphocytes (PBLs) and T cell lines [5,6]. It 
has been reported that the excess, uncleaved gpl60 is trans- 
ported from the Golgi apparatus to lysosomes, where it is 
degraded [6]. 
Previously, however, we [3] and others [4,7] reported that 
most newly synthesized gpl60 remained sensitive to endogly- 
cosidase H (endo-H) digestion throughout the chase period. It 
follows that the great majority of gpl60 retains the N-linked 
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high mannose oligosaccharide structure, and that the glyco- 
proteins have not yet been modified by N-acetylglucosaminyl- 
transferase I and Golgi a-mannosidase II in the medial Golgi 
apparatus, i.e. they have not acquired hybrid or complex su- 
gar side chains [8-10]. In contrast, gpl20 is partially endo-H- 
resistant [3,4,7], suggesting that processing of gpl60 to the 
gpl20-gp41 complex takes place prior to the creation of hy- 
brid or complex oligosaccharide units on gpl20, and that 
gpl20-gp41 but not gpl60 is further translocated through 
the medial and trans-Golgi compartments to the plasma mem- 
brane [3]. gpl60 was, however, found to be associated with 
the Golgi apparatus, which can be stained with wheat germ 
agglutinin (WGA) or antibodies to the c-myc-tagged human 
KDEL receptor [3]. 
To clarify the incompatibility between the oligosaccharide 
structures and subcellular localization of gpl60, and the re- 
ported site of degradation [6], we examined the fate of excess, 
newly synthesized gpl60 in COS-1 cells transiently expressing 
the HIV-1 env, vpu and rev genes [3]. Our results point to the 
presence of a new, distinct pathway for the degradation of env 
gpl60. A morphological chase experiment showed that gpl60 
remained associated with the Golgi region throughout i s life- 
time (i.e. it is degraded there). The degradation of gpl60 was 
insensitive to drugs that block lysosomal proteolysis. In this 
paper we describe these results and discuss possible roles of 
the disposal of gpl60 in the life cycle of HIV-1. 
2. Materials and methods 
2.1. Plasmids 
pTK19 [3], a HIV-1 rev, vpu and env expression plasmid, was used 
to study the intracellular degradation of env gpl60, pHE22M, which 
expresses the c-myc-tagged human homologue of the yeast HDEL 
receptor (ERD2), was described previously [3]. The ~-galactosidase 
expression vector, pCHll0, was purchased from Pharmacia. 
2.2. Cells and antibodies 
COS-1 cells (ATCC CRL-1650) were maintained in Dulbecco's 
modified Eagle's MEM supplemented with 10% (v/v) heat-inactivated 
fetal calf serum (D10). Pooled sera from asymptomatic HIV-l-positive 
donors, which reacted strongly with env gpl60 and the gpl20/gp41 
complex, rabbit anti-c-Myc tag antiserum, and a mouse monoclonal 
antibody specific for env gpl60 (ADP330) were as described [3]. Rab- 
bit anti-gpl20-gpl60 antiserum was a gift from Rod Daniels (Na- 
tional Institute for Medical Research, London). A mouse monoclonal 
antibody (1B5) reacting with proteins found in prelysosomes-late en-
dosomes was kindly provided by M. Marsh (MRC Laboratory for 
Molecular Cell Biology, University College, London). Cycloheximide 
(CHX) was purchased from Sigma, and HPLC-purified leupeptin and 
bafilomycin A1 (more than 95% pure) were acquired from Sigma and 
Wako Pure Chemicals (Japan), respectively. 
2.3. DNA transfection 
3 X 105 COS-1 cells per T25 flask were transfected by the calcium 
phosphate method [11], using 5 pg of expression plasmid(s) and up to 
8.4 pg of pUC12 as a cartier DNA. 1.6 pg of [3-galactosidase expres- 
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sion vector (pCHll0) was also included as an internal control to 
examine the transfection efficiencies of pTK19 and pHE22M in 
COS-1 cells. The efficiencies ranged from 10 to 20% in the series of 
experiments, but those in individual culture flasks within an experi- 
ment were comparable, as determined by a colorimetric assay (data 
not shown [12]). 
2.4. Protein labelling of transfected cells 
40-48 h after transfection, the cells were washed and incubated in 
methionine-free medium containing 10% FCS for 1 h at 37°C, and 
then pulse-labelled with [aSS]methionine (100 p.Ci/ml; 1000-1200 Ci/ 
mmol) for 30 min at 37°C. The medium was then replaced with the 
complete medium, and the cells were chased for various times up to 
21 h. At the end of the pulse and chase periods, aliquots of cells were 
removed and washed with ice-cold PBS prior to cell lysis. Acid pre- 
cipitation of proteins was performed to monitor the total incorpora- 
tion of [35S]methionine. It was found that no significant additional 
[35S]methionine was incorporated during the chase period. 
2.5. Cell lysis and immunoprecipitation 
Cellular lysates were made and immunoprecipitation was conducted 
as described [3]. Both polyclonal and monoclonal antibodies reactive 
with the envelope glycoproteins were titrated to immunoprecipitate ll 
the glycoproteins present in the cellular lysates (1:100 final dilution of 
human serum; 10 gg/ml of ADP330). The precipitates were resolved 
for analysis by SDS-polyacrylamide g l electrophoresis (SDS-PAGE) 
and ftuorography as described previously [3]. To calculate relative 
protein concentrations, the fluorographs were scanned and analyzed 
with an imaging densitometer (Model GS-670; BioRad). The optical 
density per mm 2 determined for each band was normalized to the 
specific density determined at time 0. 
To monitor the amount of gpl60 lost intracellularly by n h of chase 
(gpl60~loss), the densitometric data were fitted with the following 
equation: gpl60~loss = gpl608yn -- gpl60~ --(gpl20~ +gpl20~lo~s) - 
(gp41,~+ gp41nloss) --sgp120n. gp1608yn is the amount of gp160 
synthesized during the pulse period and was determined as 
gpl60syn = gpl601 h +gp1201 h+gp411 h. gP,~ indicates the amount 
of each envelope glycoprotein present intracellularly at n h of chase. 
gpl20 and gp41~lo~s are the amounts of gp120 and gp41 lost intracel- 
lularly by n h of chase, and were determined according to the follow- 
ing equations: gp120,~1o~ = gp1204 h- gpl20~ - sgpl20~, and 
gp41n~os~ = gp414 h -- gp41~. 
2.6. Inhibition of lysosomal proteolysis with bafilomycin A1 
The inhibition of lysosomal proteolysis was monitored by measur- 
ing the percent reduction of the intracellular degradation of 125I-la- 
belled human epidermal growth factor (125I-hEGF, more than 750 Ci/ 
mmol; Amersham) in the presence of bafilomycin A1 (Sigma). 
pTK19-transfected cells were first starved of EGF by culturing in 
Eagle's MEM containing 0.1% BSA (MEM/BSA). The cells were 
then incubated in the same medium containing 0.5 gCi of 1251- 
hEGF at 4°C for 2 h. After washing with ice-cold MEM/BSA, the 
cells were incubated in either the presence (7.8 125 nM) or absence of 
bafilomycin A1 at 37°C for 4 h. The culture medium was then col- 
lected, and the cells were washed and treated with 1 mg per ml of 
pronase (Calbiochem) at 4°C for 40 min to remove uninternalized 
ligand. The cells were then either counted directly to measure cell- 
associated total radioactivity or solubilized with a 0.5% NP-40 and 
1% Triton X-100 mixture. Cellular lysates as well as the culture med- 
ium were treated with trichloroacetic acid to determine acid-precipi- 
table and acid-soluble radioactivity, as described by Gollins and Por- 
terfield [13]. Lysosomal degradation of endocytosed 125I-hEGF [14] 
was calculated as follows: (trichloroacetic acid-soluble radioactivity 
in medium and lysate)/(medium, uninternalized ligand and cell-asso- 
ciated total radioactivity)× 100. The inhibition of lysosmal degrada- 
tion by bafilomycin A1 at each concentration tested was then deter- 
mined by calculating the percent reduction of the lysosomal 
degradation. 
2.7. Inhibition of gpl60 degradation 
pTK19-transfected cells were starved, pulse-labelled and then 
chased (up to 4 h) as described above, either without an addition 
(control) or in the presence of leupeptin (0.zl~2.1 raM). Alternatively, 
bafilomycin A1 (15.6 nM) was only included in the complete medium 
during the chase period, env gp 160 was then isolated from the cellular 
lysates by immunoprecipitation a d resolved by SDS-PAGE. The 
amount of gpl60 remaining at each time point was determined as 
described above. 
2.8. Immunofluorescence microscopy 
Cells grown on Lab-Tek tissue culture chamber slides were fixed, 
and then incubated with primary and secondary antibodies as de- 
scribed [3]. The primary antibodies used were as above. Tetramethyl- 
rhodamine isothiocyanate (TRITC)-conjugated swine anti-rabbit IgG, 
rabbit anti-human IgG (both from Dakopatts), and fluorescein iso- 
thiocyanate (FITC)-conjugated goat anti-mouse IgG (Sigma) were 
used, at the concentrations recommended by the manufacturers, as 
secondary antibodies. TRITC-conjugated wheat germ agglutinin 
(WGA, 10 I.tg/ml; E-Y Laboratories) was used to label the Golgi 
region [15]. For dual labelling, sequential antibody incubations were 
performed. For the morphological chase experiment [3], transfected 
cells were treated at 37°C with 500 gM CHX for 8 h prior to proces- 
sing for the immunofluorescence assay. Images were recorded using an 
Olympus LSM-GB200 confocal microscope with an objective of 60 × 
at zoom 1.5. 
3. Results 
3.1. Uncleared gpl60 is degraded intracellularly 
To examine HIV-1 envelope glycoprotein biosynthesis and 
cleavage, an env expression system (pTK19 [3]) was used to 
transfect COS-1 cells. The kinetics of glycoprotein synthesis 
were then monitored by metabolic labelling with 
[35S]methionine, followed by immunoprecipitation with 
pooled sera from asymptomatic HIV-l-positive donors. As 
shown in Fig. 1A, after reaching a maximal level during the 
first hour or two (see also Fig. 4B), gpl60 decayed exponen- 
tially with a half-life of approx. 7 h. Cell-associated gpl20 and 
gp41 were considerably more stable than gpl60, exhibiting 
half-lives of approx. 16 h (Fig. 1B). Relatively little of the 
gpl20 produced was secreted (Fig. 1A,B). 
Densitometry tracing of envelope glycoproteins present dur- 
ing the chase period showed that while 169.2 
(gpl601 h +gpl201 h +gp411 h) arbitrary units of gpl60 was 
initially synthesized uring the pulse period, only 10% re- 
mained after 21 h (Fig. 1B,C). Possible explanations for this 
loss include: (i) processing to the gpl20-gp41 complex, fol- 
lowed by sgpl20 release into the medium; or (ii) intracellular 
proteolysis of the uncleaved form. However, when one adds 
the amount of gpl20 secreted over 21 h to the amounts of 
gpl60, gpl20 and gp41 remaining in the cells after 21 h of 
chase, the results of a representative experiment indicated that 
76% (129.5 units) of the initial radioactivity incorporated into 
gpl60 was lost during the chase. Since less than 40% (65.6 
units after 4 h of chase) of the initial labelled gpl60 was 
processed into the gpl20-gp41 complex (Fig. 1B), the most 
likely explanation for this loss is that uncleaved gpl60 and/ 
or some of the complex formed were degraded within the 
cells. Panel C shows the kinetics of gpl60 loss during the 
chase period and that the majority of envelope glycoproteins 
degraded during the chase (70% at 21 h) is derived through 
the turnover of uncleaved gpl60. 
3.2. gpl60 is found exclusively in the Golgi region 
We subsequently aimed to establish the site where gpl60 is 
degraded. A morphological chase experiment involving CHX 
was then conducted to monitor the membrane trafficking of 
gpl60 (Fig. 2). As previously described [3], pTK19-transfected 
control COS-1 cells showed that in the steady state all the 
gpl60 resided in the WGA-stained perinuclear Golgi region 
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and the associated vesicles (Fig. 2A). Although WGA binds to 
the sialic acid and outer chain N-acetylglucosamine residues 
of complex-type oligosaccharides in the Golgi complex, it also 
allows detection of lysosomal proteins carrying similar sugar 
moieties being transported from the Golgi cisternae [9,15]. 
After 8 h of chase in the presence of CHX, some of the Golgi 
proteins labelled with WGA appeared to be transported to 
cytoplasmic non-Golgi vesicles, as shown by the increased 
cytoplasmic punctate staining as well as the concomitant re- 
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Fig. 1. Biosynthesis, processing and turnover of HIV-1 envelope gly- 
coproteins. (A) Pulse-labelled HIV-1 envelope glycoproteins were 
chased for various periods up to 21 h. The proteins were recovered 
from transfected COS-1 cells and the culture medium. Open arrow- 
heads indicate the envelope precursor, gpl60, and the mature 
gpl20/gp41 cleavage products, as well as secreted (s) gpl20. The 
mobilities of the molecular mass standards are indicated on the 
right. (B) The relative concentration of each envelope glycoprotein 
was determined as described in Section 2, using the samples shown 
in A. The optical density of each protein band was normalized to 
gpl60 present at time 0 (=end of 30 min pulse). (C) The relative 
amount of intracellular gpl60 loss was determined as described in 
Section 2, by calculation from the data shown in B. 
gpl60syn = 169.2. 
Fig. 2. Subcellular localization of HIV-1 envelope glycoproteins. (A) 
COS-1 cells transfected with pTK19 were stained with the ADP330 
monoclonal antibody and FITC-conjugated goat anti-mouse IgG 
(left), and TRITC-conjugated WGA (right). (B) COS-1 cells from 
the same culture as for (A) were incubated with CHX as described 
in Section 2. After 8 h of chase, env gpl60 (left) as well as the peri- 
nuclear Golgi region (right) were stained as above. (C) Cells from 
the same culture as for (A) were stained with rabbit anti-gpl20- 
gpl60 and TRITC-conjugated swine anti-rabbit IgG (left), and the 
1B5 anti-lysosomal ntibody and FITC-conjugated goat anti-mouse 
IgG (right). 
duction in the intensity of staining of the perinuclear Golgi 
region (Fig. 2B, right). In contrast, identical cells demon- 
strated that gpl60 selectively accumulates in the Golgi region 
during the same chase period (Fig. 2B, left), implying that the 
envelope precursor emains associated with the Golgi appara- 
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Fig. 3. Inhibition of env gpl60 degradation by leupeptin. (A) In the 
presence of various concentrations of leupeptin, pTK19-transfected 
cells were pulse-labelled and chased as described in Section 2. After 
4 h of chase, the envelope glycoproteins were recovered from the 
cells and resolved. Open arrows indicate the proteins. Molecular 
mass standards are shown on the right. C: mock-transfected con- 
trol. (B) The relative concentration of each envelope glycoprotein 
was determined as described in the legend to Fig. 1, using the sam- 
ples shown in (A). The closed circle indicates gpl60 present at the 
end of the pulse period. (C) COS-1 cells, cotransfected with pTK19 
and pHE22M, were treated with 1.7 mM leupeptin at 37°C for 
5.5 h. The cells were then stained with the ADP330 monoclonal 
antibody and FITC-conjugated goat anti-mouse IgG (left), and rab- 
bit anti-c-Myc tag antiserum and TRITC-conjugated swine anti-rab- 
bit IgG (right). 
tUS for longer than the half-life of the molecule (see above). 
To further confirm the subcellular distribution of gpl60, cells 
from the same culture were doubly stained with rabbit anti- 
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envelope polyclonal serum, and a monoclonal antibody spe- 
cific for prelysosomes and late endosomes (1B5). The immu- 
nofluorescence experiment revealed that the HIV envelope 
proteins that accumulated in the Golgi region are distinct 
from those in prelysosomes and late endosomes (Fig. 2C). It 
follows that at the steady state of expression, gpl60 appears 
not to be translocated from the Golgi apparatus into these 
prelysosomal vesicular compartments. 
3.3. Leupeptin blocks gp160 degradation in a concentration- 
dependent manner 
The above biochemical and immunocytochemical results, 
when taken together, indicate that HIV-1 env gpl60 is de- 
graded in nonlysosomal compartments within the secretory 
pathway, most likely in the Golgi complex. To determine 
whether the gpl60 turnover could be due to proteolysis within 
the Golgi cisternae, pTK19-transfected cells were incubated 
with a cysteine/serine proteinase inhibitor, leupeptin, for 60 
min before the pulse period, and the inhibitor was included 
in the pulse and chase media. Although leupeptin showed no 
effect on gpl60 degradation at concentrations up to 0.2 mM 
(data not shown), which were reported to be enough to block 
lysosomal degradation [16], the inhibitor effectively sup- 
pressed the degradation at higher concentrations (Fig. 3A). 
At 1.7 mM, the compound exerted the maximal inhibitory 
effect on gpl60 degradation, there being a 2.6-fold increase 
in the protein concentration (Fig. 3B). Under these condi- 
tions, the subcellular localization of gpl60 clearly matched 
that of a cis-Golgi resident protein, the KDEL receptor [17], 
indicating that undegraded gpl60 was last detected in the 
Golgi apparatus, not in the lysosomal compartments of the 
cells (Fig. 3C). 
3.4. Interference with lysosomal activity does not affect gpl60 
degradation 
To further confirm that the degradation of gpl60 takes 
place in the Golgi complex but not in lysosomes, we examined 
the effect on gpl60 degradation of bafilomycin A1, an inhibi- 
tor of vacuolar type H+-ATPase (V-ATPase [14]). This com- 
pound is known to inhibit lysosomal proteolysis by directly 
blocking the acidification of lysosomes (i.e. by neutralizing 
low pH-dependent lysosomal enzymes; [14]) or, at higher con- 
centrations in the exocytic route (> 100 nM in BHK-21 cells), 
by affecting vesicular transport into lysosomal compartments 
[18]. After incubation at 4°C with 125I-EGF, pTK19-trans- 
fected COS-1 cells degraded 85% of the cell surface-bound 
EGF within 4 h after warming up to 37°C (data not shown). 
Degradation of EGF was nearly completely blocked by bail- 
lomycin A1, more than 90% inhibition being observed at 15.6 
nM (Fig. 4A). In a similar experiment shown in panel B, 
however, this inhibitor of lysosomal proteolysis failed to pre- 
vent gpl60 degradation (Fig. 4B; compare columns BMA/4 h 
and 4 h), while 1.7 mM leupeptin again successfully protected 
gpl60 from nonlysosomal, Golgi degradation (Fig. 4B, col- 
umn Leu/4 h; see also Fig. 3). 
4. Discussion 
Despite the processing of HIV-1 env gpl60 into the gpl20- 
gp41 complex, followed by transport o the plasma mem- 
brane, being an essential step for the production of an infec- 
tious progeny [1,2], the cleavage takes place in a very ineffi- 
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cient manner in both HIV-l-infected PBLs (10-20% [6]) and 
heterologous expression systems (13-24% [5,6]; < 40% in this 
report). HIV-1, therefore, should make host cells provide a 
system for preventing both the overaccumulation a d surface 
expression of gpl60, since uncleaved gpl60 reaching the plas- 
ma membrane would almost certainly become incorporated 
into budding virions and, hence, the production of defective 
particles would occur [19,20]. 
In this study involving COS-1 cells we found a unique, 
nonlysosomal pathway for the selective catabolism of excess, 
uncleaved gpl60. All the data obtained in the present series of 
biochemical and immunocytochemical experiments point to 
the failure of gpl60 degraded in this pathway to reach the 
lysosomal compartments. These data include the inability to 
detect he movement of the protein out of the Golgi apparatus 
(Fig. 2), the Golgi association of undegraded gpl60 (Fig. 3), 
and the failure of an inhibitor of lysosomal proteolysis, bafi- 
lomycin A1, to block gpl60 degradation (Fig. 4). 
It was reported recently that bafilomycin A1 neutralizes not 
only lysosomal [14] but also Golgi compartments [18,21] by 
binding to the hydrophobic sector [22] of the respective resi- 
dent V-ATPase. It follows that, in the exocytic route, the site 
at which bafilomycin A1 inhibits protein degradation is deter- 
mined in a concentration-dependent manner; firstly and pri- 
marily at the lysosomes by affecting the activity of resident 
proteases [14], and secondly, at higher concentrations, in the 
Golgi apparatus by blocking protein transport, including that 
of viral glycoproteins [18], to the trans-Golgi  network, and 
then to lysosomes [18,21]. In either case, however, the degra- 
dation of gpl60 observed in the presence of bafilomycin A1 
(Fig. 4) suggests that the protein turnover occurred within the 
Golgi apparatus, where the viral protein had been retained. 
The lack of sensitivity of this degradation pathway to the 
V-ATPase inhibitor further suggests that nonlysosomal pro- 
teases are involved. Since they were effectively inhibited by the 
cysteine/serine proteinase inhibitor, leupeptin, at concentra- 
tions higher than those required for suppressing lysosomal 
endopeptidases (Figs. 3 and 4 [16,23]), these enzymes would 
probably include CaZ+-dependent proteinase II and a number 
of serine proteinases, which are nonlysosomal targets of the 
compound [16]. 
In COS-1 cells, uncleaved env gpl60 is retained and de- 
graded within the Golgi cisternae (Figs. 2-4). In addition, 
preliminary experiments involving HeLa cells showed gpl60 
being degraded in the Golgi apparatus, where the viral protein 
had accumulated (see [3]). These results are, however, in con- 
trast to what has been observed in other systems [6]. Willey et 
al. [6] reported that in PBLs and a T cell line the majority of 
uncleaved gpl60 was transported to lysosomes, where it was 
degraded. They reached this conclusion by using NH4CI and 
methionine methyl ester as lysosomotropic compounds to 
block the degradation of gpl60. Although the employment 
of different degradation pathways could simply depend on 
the host cells used [24], it should be noted that NH4C1- and 
methionine methyl ester-insensitive, nonlysosomal degrada- 
tion of gpl60 was also observed in their systems [6]. While 
more detailed experiments o analyze the Golgi degradation of 
gpl60 are required, using a variety of cell lines, these results 
indicate that the nonlysosomal degradation pathway reported 
above is not unique to COS-1 cells, i.e. it may be found in 
other cell lines. 
Furthermore, the Golgi degradation, although relevant o 
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Fig. 4. Effect of bafilomycin A1 on intracellular degradation of env 
gpl60. (A) Inhibition of the degradation of endocytosed hEGF by 
bafilomycin A1. 12~I-hEGF-adsorbed, pTK19-transfected COS-1 cells 
were incubated with various concentrations of bafilomycin A1 at 
37°C for 4 h. The percent degradation of internalized 125I-hEGF 
was determined as described in Section 2. (B) Pulse-labelled, 
pTK19-transfected COS-1 cells were chased for the various periods 
indicated on the horizontal axis, either without an addition or in 
the presence of bafilomycin A1 (BMA; 15.6 nM) or leupeptin (Leu; 
1.7 mM). env gpl60 was immunoprecipitated with ADP330 and the 
relative concentrations were determined with the samples hown on 
the horizontal axis, as described to the legend to Fig. 1. 
the HIV-1 life cycle, might have other, intrinsic roles in the 
maintenance of cellular homeostasis. For example, protein 
degradation in the endoplasmic reticulum (ER), which is 
thought o remove defective proteins from the secretory path- 
way [25], has also been suggested to explain the turnover of an 
ER resident protein [26,27]. Such an example may account for 
its role in Golgi degradation with selective retention of resi- 
dent enzymes [28] within the compartments. 
Thus, it seems reasonable that the nonlysosomal, Golgi 
degradation of gpl60 described above could both prevent 
further translocation of uncleaved gpl60 through the secre- 
tory pathway and ensure that only the mature gpl20-gp41 
complex reaches the cell surface for the subsequent produc- 
tion of an infectious progeny. Inhibition of the enzymes re- 
sponsible for gpl60 cleavage would, therefore, result in the 
proteolysis of uncleaved gpl60 and, hence, provide a basis 
for the design of antiviral strategies aimed at repression of 
virus production. 
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